OBJECTIVE： To provide reference for rational selection of anti-Stenotrophomonas maltophilia drugs. METHODS： Clinical distribution and drug resistance of 3 971 strains of S. maltophilia were retrospectively analyzed in our hospital during Jan. 2005-Dec. 2017. RESULTS： The constituent ratios of S. maltophilia in total amount of bacteria were 2.9％ （3 971/136 327） during 2005-2017. The number of the bacteria increased from 129 strains in 2005 to 468 strains in 2017， accounting for 2.3％-3.4％ in total amount of bacteria. S. maltophilia mainly came from sputum （3 130 strains， 78.8％）， fester+wound secretion （213 strains， 5.4％）， pleural effusion and ascites （170 strains， 4.3％）， and they were distributed in cerebral surgery department （742 strains， 18.7％），ICU （538 strains， 13.5％），respiratory department （401 strains， 10.1％） and hepatobiliary surgery department （366 strains， 9.2％）， etc. Drug resistance rate of the bacteria to minocycline， levofloxacin and Compound sulfamethoxazole changed from 0， 16.5％， 14.5％ in 2005 to 0.4％， 4.0％， 2.9％ in 2017， respectively； S. maltophilia had the lowest resistant to minocyclin （0-4.6％）. CONCLUSIONS： The amount of S. maltophilia in our hospital increased in each year， but its constituent ratio does not change significantly. Most of S. maltophilia are isolated from cerebral surgery department， and dominantly cause respiratory tract infection. The resistance rate of the bacteria to 3 kinds of antibiotics decreases generally， and antibiotics could be reasonably selected according to the results of drug sensitivity test.